Vident Investment Advisory, LLC Cytom X Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$9.35 - $11.41 $975,812 - $1.19 Million	-104,365 Closed	0 $0
Q1 2019 May 08, 2019	SELL	$9.5 - $19.16 $22,372 - $45,121	-2,355 Reduced 2.21%	104,365 $1.12 Million
Q4 2018 Feb 14, 2019	BUY	$12.69 - $18.61 $165,706 - $243,009	13,058 Added 13.94%	106,720 $1.61 Million
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $112,605 - $164,851	-6,242 Reduced 6.25%	93,662 $1.73 Million
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $443,870 - $616,186	20,761 Added 26.23%	99,904 $2.28 Million
Q1 2018 May 14, 2018	BUY	$21.76 - $34.22 $467,840 - $735,730	21,500 Added 37.3%	79,143 $2.17 Million
Q4 2017 Feb 15, 2018	SELL	$19.0 - $23.09 $530,024 - $644,118	-27,896 Reduced 32.61%	57,643 $1.22 Million
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $1.16 Million - $1.55 Million	85,539	85,539 $1.55 Million

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.